🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to health experts.

An International Challenge

The sexually transmitted infection are on the rise globally, with figures suggesting more than 82 million new cases annually. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the reality of growing infection rates, escalating drug resistance and the extremely scarce treatment choices currently available.”

Public health authorities are increasingly worried about the rise in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Approval

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in recent days for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Experts anticipate that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This treatment, which is employed against UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Data and Global Access

Based on data released by a major medical journal, the new drug eradicated the vast majority of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which combines an injection and a pill. The trial included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to make available and distribute the drug in many low-income and middle-income countries.

Doctors treating patients have shared positive views. Access to a single-dose, oral treatment such as this is described as a "game-changer" for public health efforts. This is considered essential to reduce the burden of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.